Cancer drug cures orphan disease skin damage
An FDA-approved cancer drug stops light sensitivity of the skin in Cockayne syndrome (CS), an ultra-rare hereditary disease characterised by premature aging, German researchers report.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2162 entries already.
Entries by Thomas Gabrielczyk
Germany to pump €1bn into breakthrough innovation
Germany’s government announced that it will create an agency for breakthrough ("jump") innovation to foster technology transfer of risky research projects with high market potential into products.
Urovant Sciences licenses OAB gene therapy
Urovant Sciences has licensed the global commercialisation rights for Ion Channel Innovations‘ gene therapy hMaxi-K for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.
Roche and Affimed in US$5bn cancer deal
Roche’s US arm Genentech has licenced Affimed NV’s ROCK platform to add multivalent antibodies, which could activate the innate immune system, to its cancer pipeline.
Foundation launches £30m award
The British Heart Foundation (BHF) will tender £30m (€33.2m) to tackle the suffering and devastation caused by heart and circulatory diseases.
Closing the gap in haemophilia therapy
About 25% of the people who suffer from haemophilia A have no therapeutic options, because their immune system forms antibodies against clotting products that can stop bleeding. Researchers and companies in the growing US$15.8bn haemophilia market are feverishly exploring new ways to identify patients at risk and offer them alternative treatments. A series of mergers and acquisitions have changed the playing field for established markets and players.
FDA greenlights Shire’s HAE mAB Takhzyro
Orphan drug leader Shire plc (Dublin), has received the FDA’s approval for its antibody lanadelumab-flyo, which prevents hereditary angioedema (HAE) attacks.
Matrikines give hint to new asthma meds
Blocking the extracellular matrix (ECM) enzyme leukotriene A4 hydrolase (LTA4H) dampens inflammation but promotes changes in the airways of mice with allergic asthma due to accumulation of the ECM degradation product PGP.
Novo Nordisk joins Evotec as drug discovery partner
Novo Nordisk and Evotec have joined forces to find new drugs in the lucrative diabetes and obesity markets.
Genkyotex cashes in €7.5m
French Genkyotex SA has secured an €7.5m gross financing to expand the scope of its Phase II product GKT831 in Primary Biliary Cholangitis (PBC).